ITPR3 and pancreatic adenocarcinoma: Then, we evaluated these findings in PAAD patients suggested that ITPR3 may be a robust factor in pancreatic cancer pathogenesis may sever as new drug targets and promising prognostic biomarkers for high pancreatic pathological cancer stage and poor disease outcome.